Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02951156 |
| Title | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) |
| Acronym | Javelin DLBCL |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Pfizer |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | POL | ITA | GBR | ESP | BEL | AUS |